William G Wierda1, John N Allan2, Tanya Siddiqi3, Thomas J Kipps4, Stephen Opat5, Alessandra Tedeschi6, Xavier C Badoux7, Bryone J Kuss8, Sharon Jackson9, Carol Moreno10, Ryan Jacobs11, John M Pagel12, Ian Flinn13, Yvonne Pak14, Cathy Zhou14, Edith Szafer-Glusman14, Joi Ninomoto14, James P Dean14, Danelle F James14, Paolo Ghia15, Constantine S Tam16. 1. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. 2. Weill Cornell Medicine, New York, NY. 3. City of Hope National Medical Center, Duarte, CA. 4. UCSD Moores Cancer Center, San Diego, CA. 5. Monash University, Clayton, VIC, Australia. 6. ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. 7. Ministry of Health, Kogarah, NSW, Australia. 8. Flinders University and Medical Centre, Bedford Park, SA, Australia. 9. Middlemore Hospital, Auckland, New Zealand. 10. Hospital de la Santa Creu I Sant Pau, Autonomous University of Barcelona, Barcelona, Spain. 11. Levine Cancer Institute, Charlotte, NC. 12. Swedish Cancer Institute Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA. 13. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN. 14. Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA. 15. Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy. 16. Peter MacCallum Cancer Center and St Vincent's Hospital and the University of Melbourne, Melbourne, VIC, Australia.
Abstract
PURPOSE: CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). METHODS: Previously untreated CLL patients age < 70 years received three cycles of ibrutinib and then 12 cycles of combined ibrutinib plus venetoclax. Patients in the MRD cohort who met the stringent random assignment criteria for confirmed undetectable MRD (Confirmed uMRD) were randomly assigned 1:1 to double-blind placebo or ibrutinib; patients without Confirmed uMRD (uMRD Not Confirmed) were randomly assigned 1:1 to open-label ibrutinib or ibrutinib plus venetoclax. Primary end point was 1-year disease-free survival (DFS) rate with placebo versus ibrutinib in the Confirmed uMRD population. Secondary end points included response rates, uMRD, and safety. RESULTS: One hundred sixty-four patients initiated three cycles of ibrutinib lead-in. After 12 cycles of ibrutinib plus venetoclax, best uMRD response rates were 75% (peripheral blood) and 68% (bone marrow). Patients with Confirmed uMRD were randomly assigned to receive placebo (n = 43) or ibrutinib (n = 43); patients with uMRD Not Confirmed were randomly assigned to ibrutinib (n = 31) or ibrutinib plus venetoclax (n = 32). Median follow-up was 31.3 months. One-year DFS rate was not significantly different between placebo (95%) and ibrutinib (100%; arm difference: 4.7% [95% CI, -1.6 to 10.9]; P = .15) in the Confirmed uMRD population. After ibrutinib lead-in tumor debulking, 36 of 40 patients (90%) with high tumor lysis syndrome risk at baseline shifted to medium or low tumor lysis syndrome risk categories. Adverse events were most frequent during the first 6 months of ibrutinib plus venetoclax and generally decreased over time. CONCLUSION: The 1-year DFS rate of 95% in placebo-randomly assigned patients with Confirmed uMRD suggests the potential for fixed-duration treatment with this all-oral, once-daily, chemotherapy-free regimen in first-line CLL.
PURPOSE: CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). METHODS: Previously untreated CLL patients age < 70 years received three cycles of ibrutinib and then 12 cycles of combined ibrutinib plus venetoclax. Patients in the MRD cohort who met the stringent random assignment criteria for confirmed undetectable MRD (Confirmed uMRD) were randomly assigned 1:1 to double-blind placebo or ibrutinib; patients without Confirmed uMRD (uMRD Not Confirmed) were randomly assigned 1:1 to open-label ibrutinib or ibrutinib plus venetoclax. Primary end point was 1-year disease-free survival (DFS) rate with placebo versus ibrutinib in the Confirmed uMRD population. Secondary end points included response rates, uMRD, and safety. RESULTS: One hundred sixty-four patients initiated three cycles of ibrutinib lead-in. After 12 cycles of ibrutinib plus venetoclax, best uMRD response rates were 75% (peripheral blood) and 68% (bone marrow). Patients with Confirmed uMRD were randomly assigned to receive placebo (n = 43) or ibrutinib (n = 43); patients with uMRD Not Confirmed were randomly assigned to ibrutinib (n = 31) or ibrutinib plus venetoclax (n = 32). Median follow-up was 31.3 months. One-year DFS rate was not significantly different between placebo (95%) and ibrutinib (100%; arm difference: 4.7% [95% CI, -1.6 to 10.9]; P = .15) in the Confirmed uMRD population. After ibrutinib lead-in tumor debulking, 36 of 40 patients (90%) with high tumor lysis syndrome risk at baseline shifted to medium or low tumor lysis syndrome risk categories. Adverse events were most frequent during the first 6 months of ibrutinib plus venetoclax and generally decreased over time. CONCLUSION: The 1-year DFS rate of 95% in placebo-randomly assigned patients with Confirmed uMRD suggests the potential for fixed-duration treatment with this all-oral, once-daily, chemotherapy-free regimen in first-line CLL.
Authors: Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd Journal: Blood Date: 2011-03-21 Impact factor: 22.113
Authors: Paolo Strati; Michael J Keating; Susan M O'Brien; Jan Burger; Alessandra Ferrajoli; Nitin Jain; Francesco Paolo Tambaro; Zeev Estrov; Jeffrey Jorgensen; Pramoda Challagundla; Stefan H Faderl; William G Wierda Journal: Blood Date: 2014-04-04 Impact factor: 22.113
Authors: Andrew W Roberts; Shuo Ma; Thomas J Kipps; Steven E Coutre; Matthew S Davids; Barbara Eichhorst; Michael Hallek; John C Byrd; Kathryn Humphrey; Lang Zhou; Brenda Chyla; Jacqueline Nielsen; Jalaja Potluri; Su Young Kim; Maria Verdugo; Stephan Stilgenbauer; William G Wierda; John F Seymour Journal: Blood Date: 2019-04-25 Impact factor: 22.113
Authors: Stephan Stilgenbauer; Barbara Eichhorst; Johannes Schetelig; Steven Coutre; John F Seymour; Talha Munir; Soham D Puvvada; Clemens-Martin Wendtner; Andrew W Roberts; Wojciech Jurczak; Stephen P Mulligan; Sebastian Böttcher; Mehrdad Mobasher; Ming Zhu; Monali Desai; Brenda Chyla; Maria Verdugo; Sari Heitner Enschede; Elisa Cerri; Rod Humerickhouse; Gary Gordon; Michael Hallek; William G Wierda Journal: Lancet Oncol Date: 2016-05-10 Impact factor: 41.316
Authors: Lindsey E Roeker; Christopher P Fox; Toby A Eyre; Danielle M Brander; John N Allan; Stephen J Schuster; Chadi Nabhan; Brian T Hill; Nirav N Shah; Frederick Lansigan; Maryam Yazdy; Bruce D Cheson; Nicole Lamanna; Arun K Singavi; Catherine C Coombs; Paul M Barr; Alan P Skarbnik; Mazyar Shadman; Chaitra S Ujjani; Hande H Tuncer; Allison M Winter; Joanna Rhodes; Colleen Dorsey; Hannah Morse; Charlene Kabel; John M Pagel; Annalynn M Williams; Ryan Jacobs; Andre Goy; Sivraj Muralikrishnan; Laurie Pearson; Andrea Sitlinger; Neil Bailey; Anna Schuh; Amy A Kirkwood; Anthony R Mato Journal: Clin Cancer Res Date: 2019-04-19 Impact factor: 12.531
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps Journal: Blood Date: 2008-01-23 Impact factor: 22.113
Authors: Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour Journal: N Engl J Med Date: 2015-12-06 Impact factor: 91.245
Authors: Matthew S Davids; Michael Hallek; William Wierda; Andrew W Roberts; Stephan Stilgenbauer; Jeffrey A Jones; John F Gerecitano; Su Young Kim; Jalaja Potluri; Todd Busman; Andrea Best; Maria E Verdugo; Elisa Cerri; Monali Desai; Peter Hillmen; John F Seymour Journal: Clin Cancer Res Date: 2018-06-12 Impact factor: 12.531
Authors: Lori A Leslie; Anthony R Mato; Lindsey E Roeker; Tatyana A Feldman; Jacob D Soumerai; Victoria Falco; Gail Panton; Colleen Dorsey; Andrew D Zelenetz; Lorenzo Falchi; Jae H Park; David J Straus; Camila Pena Velasquez; Sonia Lebowitz; Yehudit Fox; Kristen Battiato; Carissa Laudati; Meghan C Thompson; Elizabeth McCarthy; Sabrina Kdiry; Rosalba Martignetti; Teja Turpuseema; Michelle Purdom; Dana Paskalis; Hari P Miskin; Peter Sportelli Journal: Clin Cancer Res Date: 2022-09-15 Impact factor: 13.801
Authors: Thomas A Burley; Andrew Hesketh; Giselda Bucca; Emma Kennedy; Eleni E Ladikou; Benjamin P Towler; Simon Mitchell; Colin P Smith; Christopher Fegan; Rosalynd Johnston; Andrea Pepper; Chris Pepper Journal: Cancers (Basel) Date: 2022-03-22 Impact factor: 6.575